AngioDynamics’ NanoKnife System Recognised in TIME’s 2025 Best Inventions List’
LATHAM, N.Y. AngioDynamics, Inc. (NASDAQ: ANGO), a prominent medical technology company committed to enhancing vascular health and cancer treatment options, has received notable recognition for its innovative NanoKnife System, which has been included in TIME’s 2025 Best Inventions List. This prestigious annual compilation highlights exemplary products and technologies that effect meaningful changes in healthcare, lifestyle, and work environments.
The NanoKnife System, developed by AngioDynamics, employs irreversible electroporation (IRE) technology, enabling targeted destruction of cancer cells while preserving surrounding healthy tissues. This advancement marks a significant shift in cancer treatment methodologies, offering new hope to patients who may not have viable surgical options.
For over 25 years, TIME has curated its Best Inventions List to showcase groundbreaking innovations that have the potential to alter the way individuals live and receive care. AngioDynamics’ selection speaks to its commitment to advancing medical technology that prioritises patient outcomes and quality of life.
Despite this accolade, AngioDynamics has faced challenges in the stock market recently. Over the past week, the company’s shares have underperformed in comparison to the broader market and specifically against the CSIMarkets index, which tracks its competitors in the medical technology sector. This divergence highlights the volatility and complexities facing investment in emerging medical technologies, even as they make significant strides in innovation.
As AngioDynamics continues to push the boundaries of medical technology with products like the NanoKnife System, the company remains focused on its core mission of restoring healthy blood flow and broadening cancer treatment avenues, pivotal in an era where precision medicine is increasingly vital to patient care.
The recognition from TIME serves as both encouragement and a challenge for AngioDynamics to sustain its momentum in innovation while navigating the competitive and sometimes turbulent financial landscape of the medical technology industry.
Comments